Aarti Drugs Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/fh0wdkbeonik2axetxrldo55.pdf

Key Takeaways


Revenue Growth Drivers


Margin Pressure & Recovery Path

Patil: "18% would be too optimistic but first we will try to achieve that 16% EBITDA margin by Q2, Q3 and then from there onwards, with the introduction of this newer more intermediates, then probably we can look forward to increase it further."

Input Cost & Pricing Environment

Shah: "Very difficult to give any view, but looks like inflation is at top and all the governments are trying to control inflation, so demand may come down overall on commodities cycle. We expect price to come down by another three to four months, but not at the original level, but it will come down."

CAPEX & Capacity Expansion

Patil: "We had requested government that we will implement the same project at the same capacity at a lower cost, but then they said that no, you will need to meet that CAPEX requirement which we thought that unnecessary spending money upfront, there is no point and then apply for the PLI scheme."

Regulatory Catalysts

Patil: "There are a lot of indirect benefits in the terms that ... facility also has EU GMP approval and CEP approvals for a few of the big products which we manufacture and we are pretty strong in. So, there are a lot of those products in European market but because of this import alert cracking that market has been little difficult. So, if import alert is cleared, even for the European market from that facility, we can achieve a lot of growth."

Working Capital & Cash Flow


Guidance & Commitments

CommitmentSpecificsTimeline
Raw material price easingPrices expected to come down, but not to original levels"Another three to four months"
EBITDA margin recoveryAchieve 16% EBITDA margin first, then increase further with new intermediatesQ2/Q3 FY23
US FDA final response submissionFinal response to be submitted to US FDA"Towards end of H1 FY23, most probably by beginning of August"
US FDA inspectionInspection expected at Tarapur facility"By end of this financial year" (FY23)
Tarapur Greenfield trial productionTrial production to beginLast quarter of FY23
Gujarat Greenfield project completionProject completion, trial production immediate start of next financial yearEnd of FY23 / start of FY24
FY23 CAPEX₹250-350 crores, majority to Gujarat and Tarapur Greenfield projectsFY23
Debt-to-equity peakWill go as high as 0.7 during Greenfield implementationDuring FY23 implementation phase
FY26 revenue target₹4,500 crores revenue targetFY26
Long-term EBITDA marginAim for near 20% and target crossing 20% once Greenfield projects and regulated markets play outPost-Greenfield / regulated market entry
Formulations revenueTry to double revenues in three yearsThree years
Oncology formulations plantCommissioning"Coming three months"

Key Metrics

MetricQ4 FY22
Consolidated revenue₹697 cr (highest ever quarterly sale), growth of 39% YoY
Standalone revenue₹642.1 cr, growth of 42% YoY
API business revenue growth46% YoY
Formulations segment revenue₹69 cr, growth of approximately 11% YoY
Specialty chemicals and intermediates revenue₹56 cr, growth of 17% YoY
Consolidated EBITDA growth9% YoY
Consolidated PAT growth7% YoY
API standalone EBITDA margin13.2%
Consolidated operating margin~12% (per an analyst's math)
API volume growth~23% YoY
Domestic revenue growth~37% YoY, 50% of growth from volumes
Export revenue growth~50% YoY, 30–32% of growth from volumes, 18–19% from freight rate
Net debt-to-equity0.52x as of March 31, 2022
CAPEX incurred in FY22₹145 cr
Planned CAPEX for FY23₹250 cr to ₹350 cr